New therapeutic and diagnostic solutions are key components for improving health and wellbeing in the global setting including low- and middle-income countries. Despite the scarcity of resources, this can be achieved under the right conditions, and the associated risks and costs successfully addressed. The societal need for new treatments is clear, even where the economic case for pursuing and launching the necessary drugs might initially seem tenuous.
A vicious circle is often associated with diseases predominantly occurring in low- and middle-income countries. Poor health severely hamper local development, reducing purchasing power further, making the prospects of financial return of investment limited.
The answer lies in building partnerships that are able to offer a solution to both funding issues and gaps in expertise. Lygature brings organizations together to develop pharmaceutical tools that alleviate the disease burden in vulnerable populations. We help to pool resources, secure funding, share costs, and mitigate risks.
An international drug discovery project together with Medicines for Malaria Venture.
Goal: seeking novel ways to block malaria transmission and to prevent relapse.
Japanese-Dutch partnership studying Schistosoma antigens with diagnostic potential.
Goal: Developing a fast, simple, antibody test for diagnosing schistosomiasis in patient blood or urine.
A European collaboration progressing Gram-Negative antibiotics from lead optimization up to completion of Phase I trials.
Goal: to operate a consortium of experts, representing all the critical skills and experience required to progress potential Gram(-) antibiotics from lead optimisation up to completion of Phase I trials.
A European consortium of experts, representing all the critical skills and experience required to progressing Gram-Negative antibacterials from lead optimization up to completion of Phase I trials.
Goal: to produce three drug candidates in different phases of development: one Phase II ready one Phase I ready and one preclinical candidate.